# Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels

> **NCT00143624** · NA · COMPLETED · sponsor: **University of British Columbia** · enrollment: 50 (estimated)

## Conditions studied

- Atherosclerosis
- HIV Infections

## Interventions

- **DRUG:** Rosiglitazone maleate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00143624
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2009-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143624, "Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00143624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*